CAR-T Cells + Keytruda: New Immunotherapy for Pleural Mesothelioma?
Researchers at a top US cancer center are experimenting with a new approach to immunotherapy for pleural mesothelioma – with…
-
-
Study May Lead to Safer Immunotherapy for Mesothelioma
New research conducted in Europe and at Harvard University may open the door to safer immunotherapy for mesothelioma patients. Immunotherapy… -
Early Data Show Promise for Galinpepimut-S and Opdivo in Mesothelioma Patients
A combination of the immunotherapy drugs galinpepimut-S and Opdivo may give mesothelioma patients a few extra months, according to newly-released… -
Europe | Immunotherapy | International | New Drugs | New Studies | Research | Treatments
Immunotherapy Treatment ONCOS-102: News Keeps Getting Better
The news just keeps getting better for the virus-based immunotherapy treatment ONCOS-102. Norweigian drug maker Targovax recently released the final… -
Effectiveness of Keytruda: Dutch Study Offers Clues for Prediction
A new Dutch study offers some clues that might help doctors predict the effectiveness of Keytruda (pembrolizumab) in individual mesothelioma… -
Breath Test Could Predict Mesothelioma Immunotherapy Response
New research shows a breath test called an eNose might help doctors determine which mesothelioma patients are most likely to… -
Inflammation Protein May Impact Drug Therapies for Mesothelioma
A protein involved in the inflammatory process could impact how patients respond to drug therapies for mesothelioma. The news comes… -
Latest Keytruda Study Shows Limited Results for Most Mesothelioma Patients
Results of the latest Keytruda study show the drug works well for a select few mesothelioma patients, but not well… -
Different Mesothelioma Subtypes: Gene Study Could Lead to Targeted Treatments
A group of European pathologists say the different mesothelioma subtypes have significant differences in their pattern of gene expression. Exploiting… -
Europe | Genetics | Immunotherapy | International | Research | Treatments
Long-Term Mesothelioma Survival With Immunotherapy Combination
An immunotherapy combination of tremelimumab and durvalumab has resulted in long-term survival for some mesothelioma patients in a new follow-up…
